Current treatment guidelines for this type of breast cancer recommend use of multidrug chemotherapy (i.e., a sequential combination of an anthracycline-containing regimen and a taxane, or simultaneous use of a taxane and platinum) combined with anti-HER2 agents [2, 3]. The gene discussed is ERBB2; the disease is breast carcinoma.